Gastrointestinal Cancer
Adrenal, pancreas and liver tumors have been successfully treated with stereotactic body radiation therapy (SBRT)/stereotactic ablative body radiotherapy (SABR), and a sufficient amount of data has been published to begin quantitative analyses of tumor control and dose tolerance. Dose-response models are the foundation of dose tolerance guidelines in the Rubin and Casarett textbook (1), the Emami paper (2), and in QUANTEC (3), and the goal of the High Dose per Fraction/Hypofractionated Treatment Effects in the Clinic (HyTEC) project is to apply this methodology to SBRT. HyTEC is organized by disease site to review and analyze the relevant SBRT literature. In this session, we will be presenting models that were derived from the published data to predict the dose response relationship between hypofractionated SBRT doses and tumor control probability for adrenal, pancreas and liver tumors, as well as normal tissue complication rates of liver and the gastrointestinal tract after abdominal SBRT.
Disclosure:
Employment
Johns Hopkins University: Employee: Employee
Ownership
DiversiLabs, LLC: Patent/License Fees/Copyright
Leadership
AAPM SBRT Working Group: Co-Chair
Panel 01 - (INTERACTIVE) HyTEC Report: SBRT/SABR in Abdominal Regions
Sunday, October 21
1:15 PM – 2:45 PM
Sunday, October 21
2:40 PM – 2:45 PM
Disclosure:
Employment
Memorial Sloan Kettering Cancer Center: Attending Physicist: Employee
Leadership
AAPM: Co-chair of WGSBRT, member at large of Board of Directors
Panel 01 - (INTERACTIVE) HyTEC Report: SBRT/SABR in Abdominal Regions
Sunday, October 21
1:15 PM – 2:45 PM
The asset you are trying to access is locked. Please enter your access key to unlock.